The estimated Net Worth of Waldemar Priebe is at least $679 mil dollars as of 6 December 2022. Dr Priebe owns over 94,298 units of Moleculin Biotech Inc stock worth over $376,337 and over the last 7 years he sold MBRX stock worth over $302,960.
Dr has made over 2 trades of the Moleculin Biotech Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 94,298 units of MBRX stock worth $132,960 on 6 December 2022.
The largest trade he's ever made was selling 100,000 units of Moleculin Biotech Inc stock on 16 August 2017 worth over $170,000. On average, Dr trades about 48,575 units every 485 days since 2017. As of 6 December 2022 he still owns at least 156,807 units of Moleculin Biotech Inc stock.
You can see the complete history of Dr Priebe stock trades at the bottom of the page.
Dr. Waldemar Priebe Ph.D. is the Co-Founder & Chairman of Scientific Advisory Board at Moleculin Biotech Inc.
Waldemar's mailing address filed with the SEC is C/O CNS PHARMACEUTICALS, INC., 100 WEST LOOP SOUTH, SUITE 900, HOUSTON, TX, 77027.
Over the last 8 years, insiders at Moleculin Biotech Inc have traded over $340,000 worth of Moleculin Biotech Inc stock and bought 433,338 units worth $371,310 . The most active insiders traders include Walter V Klemp, John M Climaco y Waldemar Priebe. On average, Moleculin Biotech Inc executives and independent directors trade stock every 75 days with the average trade being worth of $69,293. The most recent stock trade was executed by Walter V Klemp on 2 July 2024, trading 982 units of MBRX stock currently worth $2,357.
moleculin biotech, inc. is a preclinical pharmaceutical company focused on the development of anti-cancer drug candidates, some of which are based on discoveries made at m.d. anderson cancer center. our lead product candidate is annamycin, a phase ii clinical stage anthracycline for the treatment of relapsed or refractory acute myeloid leukemia, more commonly referred to as aml. we also have two pre-clinical small molecule portfolios, one of which is focused on the modulation of hard-to-target tumor cell signaling mechanisms and the recruitment of the patient’s own immune system. the other portfolio targets the metabolism of tumors.
Moleculin Biotech Inc executives and other stock owners filed with the SEC include: